Once riding high on the success of its COVID-19 vaccine, Pfizer (PFE) now finds itself in a prolonged slump. Although the stock has recovered somewhat from its lows, it remains more than 50% below its 2021 all-time high. The century-old pharmaceutical leader now faces a critical year in 2026, caught between attracting income investors with a tempting 6.6% dividend yield and overcoming three steep challenges that threaten its turnaround.
A key driver behind Pfizer’s stock decline is its absence from the booming market for GLP-1 drugs, widely used for diabetes and weight loss. After an internal candidate failed, Pfizer has been playing catch-up through acquisitions and a deal to distribute a Chinese-developed GLP-1 pill—if approved. Still, it remains a distant follower in a field dominated by Eli Lilly and Novo Nordisk. Progress in this arena in 2026 will be essential to restoring investor confidence in Pfizer’s innovation pipeline.
Adding to the pressure is the approaching loss of exclusivity for several key drugs. Pfizer’ oncology treatment Ibrance is expected to face generic competition in 2027, followed by the cardiovascular drugs Eliquis and Vyndaqel in 2028. While patent expirations are routine in the industry, 2026 represents the last full year before revenue from these blockbusters may begin to shrink. The clock is ticking for Pfizer to fill the coming revenue gap with new products.
Pfizer’s high 6.6% dividend yield comes with a warning sign: its dividend payout ratio is hovering around 100%. Although dividends are funded by cash flow—not earnings—such a high ratio raises concerns when combined with significant R&D needs, recent acquisitions, and the looming patent cliff. In 2026, the company must demonstrate it can sustain its dividend while navigating these financial headwinds. For conservative income investors, this remains a clear risk.
Despite its struggles, Pfizer remains a pharmaceutical heavyweight with the resources to engineer a recovery. The stock represents a potential turnaround story, but its high dividend could be both an attraction and a vulnerability.
As 2026 approaches, investors may want to keep Pfizer on their watchlist. The company’s ability to advance its GLP-1 pipeline, manage its patent transitions, and maintain a sustainable dividend will determine whether it can climb back from its slump—or remain stuck at a discount. The coming year will test both Pfizer’s strategy and the market’s patience.
